As biologics, biomarker-enriched trials and real-world evidence reshape the COPD landscape, sponsors face both new opportunities and increasing complexity. Success depends on translating these advances into effective cli...
Biotech
Developing transformative therapies with small & mid-sized biopharma companies requires a flexible approach
PlayFrom here to where?
Plotting a course to bring APAC-developed drugs to the world
Download Global and China biotech survey reports
Two new survey reports of 260+ Global and China-based biotech leaders are ready to download.
Driving biotech success at every milestone
Biotech companies are pioneering the future of medicine from genomic breakthroughs to first-in-class immunotherapies. With focused pipelines and bold ambitions, many biotechs operate without the full infrastructure of larger organizations, making speed, precision, and strategic support essential.
ICON delivers the expertise, technology, and global reach to turn biotech innovation into impact. Our empowered structure enables fast decision-making and flexible engagement, backed by the scale of one of the world’s most innovative CROs.
Our dedicated biotech teams are built to understand your unique pressures and priorities, collaborating closely, sharing ownership, and delivering results at every stage of development.
Our four-pillar approach, Patients, People, Process, and Partnership, is designed to transform biotech ambition into real-world impact. By combining patient-centric strategies, expert talent, streamlined operations, and collaborative engagement, ICON empowers you to deliver life-changing therapies faster.
Emerging biotech funding
As new funding models and investor priorities reshape the biotech landscape, companies must navigate a dynamic environment with agility and foresight to secure the capital needed for innovation.
Behind Biotech
Our experts bring more than scientific knowledge - they bring purpose, perspective, and a commitment to partnership.
Partnering with biotechs to transform ideas into life-changing therapies.
ICON provides end-to-end capabilities, from early-phase design to market access; ensuring agility, scalability, and scientific excellence throughout the development journey.
-
Тailored clinical development
8,000 professionals dedicated to biotech delivering agile, customized solutions built around your needs.
-
Consulting and advisory services
Strategic guidance from early development through to commercialization.
-
Therapeutic expertise
Deep experience across therapeutic areas, from first-in-human to late-phase trials.
-
Tools and technologies
Innovative platforms that accelerate research and enhance data-driven decisions.
Emerging biotech, empowered for investment
ICON partners with biotech innovators to sharpen funding strategies, align with investor expectations, and drive value across every stage of development.
Optimising biotech funding whitepaper series
In this two-part whitepaper series on biotech funding, we firstly share insights on how biotechs can secure funding in a highly competitive market, and then shed light on the opportunities available to utilise these funds more effectively and efficiently.
Early phase challenges for biotechs
This whitepaper explores the growing challenges facing biotech during early phase drug development, and how these can be navigated to ensure the best possible outcomes.
Case studies
Explore our biotech case study library showcasing real-world success stories where bold ambition meets ICON’s expertise.
Empowering biotech innovation at every stage of development.
Through advanced analytics, global trial expertise, and strategic partnerships, ICON enables biotechs to streamline processes and achieve faster, smarter outcomes.
Early, precise and efficient
The methods and technologies advancing Alzheimer’s and Parkinson’s R&D
In this CNS whitepaper, which includes extracts from our survey of over 120 neurodegenerative therapeutic developers, we examine how innovative methodologies and technologies are being implemented to improve the success rate of clinical trials across a range of neurodegenerative disorders.
Procedural and regulatory know-how for China biotech in the EU
How to navigate EU MAA regulations and registration
Learn how to navigate the European Medicines Agency registration and regulation procedures and gain access to a potential patient pool of 500 million people.
2023 biotech sector survey
The biotech industry stands at a pivotal moment, navigating funding challenges with resilience and adaptability. After a period of remarkable growth and investment, the landscape shifted abruptly in 2022, and 2023 continued to present its own set of challenges.
De-risking clinical development of precision medicines in oncology
This whitepaper reviews the most pressing challenges and opportunities facing the oncology therapeutic landscape in the emerging era of precision medicine, and reports on how those opportunities and challenges vary by organisational size and region.
Digital disruption
The clinical research industry is making strides in technological innovation, with small but steady increases to the percentage of companies implementing and piloting digital technologies. However, our 2024 digital disruption survey conducted with Citeline shows a slower pace of innovation than predicted by the 2019 survey. Why is this the case?
Obesity and beyond
Embracing multi-indication potential during clinical development
This whitepaper explores the strategic rise of multi-indication drug development for obesity and its comorbidities, offering insights into clinical trial design, regulatory pathways, and commercial opportunities based on recent industry trends and survey data.
.jpeg?crop=yes&w=1017&h=1017&a=325,0&itok=ZQ_TVcyw "obesity_scan_icons"){kind=icon}
Building strong foundations: regulatory insights for biotechs.
Through early engagement strategies, deep procedural expertise, and global regulatory insight, ICON equips biotechs to anticipate challenges, streamline submissions, and accelerate access to key markets worldwide.
Early engagement and regulatory considerations for biotech
Gain insight into the common questions small and emerging biotech companies face, and the importance of early engagement and regulatory affairs when developing an asset and considering a drug development partner.
Biotech blogs and media contributions
-
Media article: From confidence to capital: Positioning biotech for the next growth cycle
How can biotechs position themselves for the next growth cycle? Deepali Suri shares insights on investor readiness, AI, global development strategies and emerging opportunities across biotech.
-
Media article: Why Europe, not America, may be Chinese sponsors’ smartest move
As Chinese sponsors expand globally, Europe offers a stable, science-driven regulatory environment and broad market access across the region. Planning for EMA requirements from the outset helps accelerate approvals, minimise costly study adaptations and support long-term commercial success.
-
Media article: Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
China's rapid rise as a hub for testing experimental, next-generation medicines is outpacing the industry's ability to build the workforce needed to take those products global.
-
Media article: It’s complicated! When APAC global ambition meets regulatory reality
While not all sponsors plan to market treatments beyond the country of origin, many do. Choosing which regulatory route offers the most strategic advantages and which market is strategically important.
-
Media article: Banyan BioInnovations debuts with $100M+ and ICON
A new biotech investment firm launches with more than $100 million in initial commitments from life science investors. ICON is both a strategic collaborator and an equity investor.
-
Media article: Banyan BioInnovations launces with ICON support
$100M Biotech investment fund announces collaboration with ICON designed to improve trial execution and design, as well as commercialisation strategy.
-
Media article: When ambition meets ambiguity: The trends and sentiments shaping biotech in 2026
Deepali Suri, President ICON Biotech, provides insights into what biotech leaders anticipate in the coming two years, the therapies and modalities they’re focused on now and what macro and micro factors are impacting their operations.
-
Media article: China biotech continues its growth trajectory
Yao Zhong, vice president general manager for ICON China Mainland and Hong Kong, discusses latest survey results on the Chinese biotech market.
Start the conversation
Start the conversation with our biotech team to explore how ICON can accelerate your clinical development and deliver investor-ready trial strategies tailored to your goals.
